CRISPR Therapeutics Announces Chief Financial Officer Transition
Key Highlights
- ➤CFO Raju Prasad steps down effective today to pursue external opportunities
- ➤A.J. Silver succeeds Prasad as CFO, effective immediately
- ➤A.J. Silver has led CRISPR Therapeutics finance roles since joining in October 2018
- ➤CRISPR Therapeutics says CASGEVY is approved for sickle cell disease and beta thalassemia
Expert Statements
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“Raju has been a trusted partner to me and a wonderful colleague during his time at CRISPR Therapeutics”
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“His thoughtful leadership helped build a strong finance organization, strengthen our balance sheet, and deepen our relationships with the investment community.”
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“On behalf of everyone at CRISPR Therapeutics, I thank Raju for all he has done and wish him every success in his next role.”
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“I am excited for A.J. to assume his new role as CFO”
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“Over the past eight years, A.J. has been a key leader across our finance organization, and his deep knowledge of our business combined with his strong operational experience makes him exceptionally well suited to lead us going forward.”
Raju Prasad, Former Chief Financial Officer of CRISPR Therapeutics
“Serving as CFO of CRISPR Therapeutics has been an honor”
Raju Prasad, Former Chief Financial Officer of CRISPR Therapeutics
“I am grateful to Sam, the Board of Directors of CRISPR Therapeutics, and the Company’s talented team for all we have accomplished together.”
Raju Prasad, Former Chief Financial Officer of CRISPR Therapeutics
“It has been inspiring to work alongside people so committed to bringing transformative medicines to patients, and I am confident in the Company's future.”
Raju Prasad, Former Chief Financial Officer of CRISPR Therapeutics
“I have decided this is the right time for me to take the next step in my career, and I look forward to following CRISPR Therapeutics’ continued progress.”
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J. Silver, the Company's Senior Vice President of Finance, will succeed Dr. Prasad as Chief Financial Officer. This transition will be effective today.
“Raju has been a trusted partner to me and a wonderful colleague during his time at CRISPR Therapeutics," said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. "His thoughtful leadership helped build a strong finance organization, strengthen our balance sheet, and deepen our relationships with the investment community. On behalf of everyone at CRISPR Therapeutics, I thank Raju for all he has done and wish him every success in his next role.”
Get started
Create a free account to read the full story.